Welcome to BDA

  "The future of molecular targeted therapy requires a detailed understanding of translational R&D and economics."


Navigation Home Navigation Navigation Publications Navigation News Navigation Events Navigation Links Navigation Contacts Navigation Information

    Sat 25 May 2013

Don't miss our
upcoming events

Brussels, 4-5 Oct. 2012
Preclinical/early clinical biomarker discovery

Vienna, 29 -30 Nov 2012
Present and future breast cancer management: bench to bedside and back

_______________________

Latest events

          Disclaimer

 
BDA Information
Click here to request information from BDA

Change text size

© 2009 Biotherapy Development Association




BDA Scientific Advisors
The BDA Scientific Advisors consists of the following eminent members:

Professor Gillies Vassal



Gilles Vassal, MD, PhD, Professor of Oncology, Direction of Clinical and Translational Research, Institut de Cancérologie Gustave-Roussy

Professor Michael Marty

Professor Michel Marty,Director of Centre for Therapeutic Innovation in Oncology and Hematology in Saint Louis University Hospital (Paris, France)
Professor Angus Dalgleish

Prof. Angus Dalgleish, Oncology Division, St George's Medical School, London, UK
Professor Ian Ellis

Prof Ian Ellis Professor of Cancer Pathology at the University Hospital, Nottingham, UK
Dr Steven Hirschfeld

Dr Steven Hirschfeld - Associate Director Clinical Research, National Institute of Child health and Human Development, Bethesda, USA
Professor Pat Price

Prof. Pat Price Director of Radiation Oncology, University of Manchester UK
 

Prof. Bernie Fox Director of Oncology Research, Earle A. Chiles Research Institute, Portland, Oregon, USA

 

Professor Giampietro Gasparini University Hospital, Rome, Italy


 

Prof. Gustav Gaudernack Director of Oncology, University of Oslo, Norway

 

Prof. Rolf Kiessling, Kalrolinska Institute, Stockholm, Sweden

 

Prof. Klaus Pantel Director Institute for Tumour Biology, University of Hamburg, Germany

 

Prof. Jamie Zwiebel, Chief for Biologics Evaluation, National Cancer Institute, Maryland, USA